The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2015

Filed:

Dec. 23, 2008
Applicants:

Ian Maclachlan, Mission, CA;

Adam Judge, Vancouver, CA;

Inventors:

Ian MacLachlan, Mission, CA;

Adam Judge, Vancouver, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); C12N 15/113 (2010.01); C12N 15/88 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); C12N 15/88 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3521 (2013.01); C12N 2310/3525 (2013.01); C12N 2310/3533 (2013.01); C12Y 207/11021 (2013.01);
Abstract

The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.


Find Patent Forward Citations

Loading…